Mielóma multiplex: nyitott vizsgálatok itt: Görögország
40 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. nov. 10.. Ask the study team whether a trial fits you.
1. fázisToborozTrial-stage medicine
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Where
- Athens
- Age
- 18 év and over
- People
- 317 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05137054EU 2023-506247-42-00Regiszter frissítve: 2026-11-05
1/2. fázisToborozTrial-stage medicine
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Athens
- Age
- 18 év and over
- People
- 150 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07455851EU 2025-522776-93-00Regiszter frissítve: 2026-11-05
2. fázisToborozResearch participation
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
- Where
- Alexandroupoli, Athens, Thessaloniki
- Age
- 18 év and over
- People
- 240 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06189833EU 2023-505221-14-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Alexandroupoli, Athens, Ioannina, Patra, Thessaloniki
- Age
- 18 év and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761EU 2024-519504-27-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Where
- Athens, Patras, Thessaloniki
- Age
- 18 év and over
- People
- 270 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07393282EU 2025-523252-31-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Athens, Thessaloniki
- Age
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222EU 2023-503442-30-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Athens, Thessaloniki
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07258511EU 2025-522007-18-00Regiszter frissítve: 2026-11-03
2. fázisToborozTrial-stage medicine
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Alexandroupoli, Athens, Piraeus, Rio, Thessaloniki
- Age
- 18 év and over
- People
- 230 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07589634Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Where
- Alexandroupoli, Athens, Thessaloniki
- Age
- 18 év and over
- People
- 1000 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07665450Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Athens, Thessaloniki
- Age
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085Regiszter frissítve: 2026-10-30
2. fázisToborozTrial-stage medicine
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
- Where
- Athens, Thessaloniki
- Age
- 18 év and over
- People
- 127 worldwide
- Run by
- Karyopharm Therapeutics Inc
See details and how to joinNCT04414475EU 2024-511608-18-00Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Athens, Patras
- Age
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479EU 2024-515279-37-00Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Athens, Ioannina, Thessaloniki
- Age
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020EU 2024-514139-50-00Regiszter frissítve: 2026-10-27
1/2. fázisToborozTrial-stage medicine
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Where
- Alexandroupoli, Athens
- Age
- 18 év and over
- People
- 246 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04973605EU 2023-507751-30-00Regiszter frissítve: 2026-10-26
3. fázisToborozResearch participation
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
- Where
- Athens, Chaïdári, Ioannina
- Age
- 18 év and over
- People
- 206 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-523815-12-00EU 2025-523815-12-00Regiszter frissítve: 2026-10-19
2. fázisCsak meghívásosTrial-stage medicine
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Where
- Athens, Pátrai
- Age
- 18 év and over
- People
- 70 worldwide
- Run by
- Sanofi
See details and how to joinNCT05669989Regiszter frissítve: 2026-10-15
No phaseToborozResearch participation
Early Detection and Screening of Hematological Malignancies - SANGUINE
- Where
- Athens
- Age
- 18 év and over
- People
- 3000 worldwide
- Run by
- JaxBio Ltd
See details and how to joinNCT05735704Regiszter frissítve: 2026-10-15
3. fázisToborozResearch participation
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Where
- Alexandroupoli, Athens, Thessaloniki
- Age
- 18 év and over
- People
- 423 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-526654-14-01EU 2026-526654-14-01Regiszter frissítve: 2026-10-14
1/2. fázisToborozTrial-stage medicine
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- Where
- Athens
- Age
- 18 év and over
- People
- 258 worldwide
- Run by
- Sanofi
See details and how to joinNCT04643002Regiszter frissítve: 2026-10-13
3. fázisToborozTrial-stage medicine
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Athens, Ioannina
- Age
- 18 év and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480EU 2024-518420-80-00Regiszter frissítve: 2026-10-13
3. fázisToborozTrial-stage medicine
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Where
- Athens, Thessaloniki
- Age
- 18 év and over
- People
- 380 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07555938EU 2025-524028-23-00Regiszter frissítve: 2026-10-13
3. fázisToborozTrial-stage medicine
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Where
- Alexandroupoli, Athens, Thessaloniki
- Age
- 18 év and over
- People
- 1594 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT05243797EU 2023-510384-36-00Regiszter frissítve: 2026-10-07
3. fázisToborozTrial-stage medicine
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Athens, Ioannina
- Age
- 18 év and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07518186Regiszter frissítve: 2026-09-25
2. fázisToborozResearch participation
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
- Where
- Alexandroupoli, Athens, Patras, Pireas, Thessaloniki
- Age
- 18 év and over
- People
- 123 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-524793-42-00EU 2025-524793-42-00Regiszter frissítve: 2026-09-11
1/2. fázisToborozTrial-stage medicine
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Where
- Athens
- Age
- 18 év and over
- People
- 62 worldwide
- Run by
- Celgene
See details and how to joinNCT06988488EU 2025-522090-11-00Regiszter frissítve: 2026-09-02
Minden vizsgálat (Mielóma multiplex) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.